Surgery, Gastroenterology and Oncology

Data sharing policy

Surgery, Gastroenterology and Oncology follows the reporting standards and availability of data, materials, code and protocols established by Springer Nature and by the American Society of Clinical Oncology (ASCO). Authors will be required to make materials, data, code, and associated protocols promptly available to readers without undue qualifications. Any restrictions on the availability of materials or information must be disclosed to the editors of Surgery, Gastroenterology and Oncology at the time of the manuscript submission and disclosed in the submitted manuscript.

After publication, readers who encounter refusal by the authors to comply with these policies should contact the Editor-in-Chief of Surgery, Gastroenterology and Oncology. In cases where editors are unable to resolve a complaint, the journal may refer the matter to the authors' funding institution and/or publish a formal statement of correction, attached online to the publication, stating that readers have been unable to obtain necessary materials to replicate the findings.

Data Availability

Supporting data must be made available to editors and peer reviewers at the time of submission for the purposes of evaluating the manuscript. Large data sets or videos should be shared via existing public repositories while observing confidentiality rules. For additional information on our data sharing policies, authors may contact the Publisher for advice.

For biological materials such as mutant strains and cell lines, Surgery, Gastroenterology and Oncology recommends authors to use established public repositories, for example, Jackson Laboratory, the European Mouse Mutant Archive (EMMA), the European Conditional Mouse Mutagenesis Program (EUCOMM), the Knockout Mouse Project (KOMP), Addgene, RIKEN Bioresource Centre, the Mutant Mouse Regional Resource Centers, American Type Culture Collection (ATCC), and provide accession numbers in the manuscript.

For cell lines, weencourage deposition of new cell lines in repositories that will distribute them with certificates of authentication. Alternatively, we recommend that authors establish a profile of their new cell lines to allow future authentication. The distribution of human cell lines used in research should not be hindered by restrictions from donors. Researchers developing cell lines must investigate and disclose any restrictions associated with the tissue they are using.

Clinical studies

Surgery, Gastroenterology and Oncology supports study pre-registration of including clinical trials (on clinicaltrials.gov databaseor a similar public repository that matches the criteria established by ICMJE). If registered, the registry record should be provided at the time of manuscript submission.

Authors reporting phase II and phase III randomized controlled trials must refer to the CONSORT Statement for recommendations to facilitate the complete and transparent reporting of trial findings. Reports that do not conform to the CONSORT guidelines may need to be revised before formal review.Authors reporting prognostic studies with tumor markers are encouraged to follow the REMARK guidelines for complete and transparent reporting.

For describing human biospecimens, we recommend referring to the Biospecimen Reporting for Improved Study Quality (BRISQ) reporting guidelines.

The following specifically relates to clinical trials that include clinical outcome data, including survival and toxicity. We encourage the authors of clinical trials of therapeutic or diagnostic interventions to submit a data sharing statement with their manuscript, specifically as it relates to clinical outcome data.

The US Office for Human Research Protections has indicated that, provided the appropriate conditions are met by those receiving them, the sharing of deidentified individual participant data from clinical trials does not require separate consent from trial participants. Specific elements to enable data sharing statements that meet these requirements have been adopted at ClinicalTrials.gov.

Availability of reagents

We encourage the Authors of articles in Surgery, Gastroenterology and Oncologyto place no restrictions on the redistribution of patient-derived cell lines or other tissue. We also encourage them to authenticate all reagents, and state in the Methods section the method of authentication used, the results and date of testing. Authentication test results must be provided upon request. Mycoplasma contamination testing status of cell lines must also be reported.